The FDA is set to request Sarepta Therapeutics to halt shipments of its gene therapy, Elevidys, after a third patient's death ...

Sarepta (NASDAQ:SRPT) has now seen a third fatal incident in its gene therapy trials due to acute liver failure. That ...